WP
RVMD icon

Woodline Partners’s Revolution Medicines RVMD Stock Holding History

Woodline Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375M Sell
2,002,863
-503,707
-20% -$73.6M 1.16% 8
2026
Q1 		$244M Buy
2,506,570
+5,675
+0.2% +$573K 0.92% 9
2025
Q4 		$199M Sell
2,500,895
-414,988
-14% -$27.2M 0.77% 15
2025
Q3 		$136M Buy
2,915,883
+311
+0% +$12.2K 0.64% 20
2025
Q2 		$107M Sell
2,915,572
-971,464
-25% -$37.3M 0.57% 16
2025
Q1 		$137M Buy
3,887,036
+1,323
+0% +$53.7K 0.89% 7
2024
Q4 		$170M Buy
3,885,713
+452,000
+13% +$22.8M 1.15% 5
2024
Q3 		$156M Buy
3,433,713
+142,922
+4% +$6.22M 1.31% 4
2024
Q2 		$128M Sell
3,290,791
-506,357
-13% -$18.9M 1.22% 6
2024
Q1 		$122M Buy
3,797,148
+837,108
+28% +$24.8M 1.13% 8
2023
Q4 		$84.9M Sell
2,960,040
-185,405
-6% -$4.46M 0.92% 18
2023
Q3 		$87.1M Sell
3,145,445
-615,930
-16% -$18.3M 1.02% 18
2023
Q2 		$101M Buy
3,761,375
+338,403
+10% +$8.3M 1.19% 12
2023
Q1 		$74.1M Buy
3,422,972
+2,972,957
+661% +$73.2M 1.01% 16
2022
Q4 		$10.7M Sell
450,015
-113,866
-20% -$2.42M 0.14% 195
2022
Q3 		$11.1M Buy
563,881
+300,082
+114% +$6.59M 0.16% 187
2022
Q2 		$5.14M Sell
263,799
-2,067,596
-89% -$40.2M 0.08% 256
2022
Q1 		$59.5M Sell
2,331,395
-598,643
-20% -$13M 0.97% 17
2021
Q4 		$73.7M Buy
2,930,038
+2,060,554
+237% +$58.1M 1.06% 13
2021
Q3 		$23.9M Buy
869,484
+17,892
+2% +$521K 0.39% 69
2021
Q2 		$27M Buy
851,592
+9,530
+1% +$333K 0.5% 49
2021
Q1 		$38.6M Buy
842,062
+34,932
+4% +$1.57M 0.86% 28
2020
Q4 		$32M Buy
807,130
+779,219
+2,792% +$30.8M 0.85% 29
2020
Q3 		$971K Buy
+27,911
New +$773K 0.03% 172
2020
Q2 		– Sell
-54,867
Closed -$1.2M – 182
2020
Q1 		$1.2M Buy
+54,867
New +$1.52M 0.09% 124

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Woodline Partners's RVMD Position: Q2 2026 in Review

Woodline Partners reduced its Revolution Medicines (RVMD) stake by 20% in Q2 2026, selling an estimated $73.6M and leaving 2,002,863 shares worth $375M. The position accounts for 1.16% of the portfolio, ranked #8.

Woodline Partners first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Woodline Partners held 2,002,863 shares of Revolution Medicines worth $375M as of Q2 2026.
  • Woodline Partners sold 503,707 Revolution Medicines shares in Q2 2026, an estimated $73.6M.
  • Revolution Medicines made up 1.16% of Woodline Partners's portfolio in Q2 2026, its #8 holding.
  • Woodline Partners first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.